Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apeiron Biologics Begins Phase 1 Trial to Treat Covid-19 with Inhaled APN01
Details : Primary study objective is the evaluation of safety and tolerability of single ascending doses (SADs) and multiple ascending doses (MADs) of inhaled APN01 when administered via a jet nebulizer in healthy subjects.
Product Name : APN01
Product Type : Enzyme
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial.
Product Name : APN01
Product Type : Enzyme
Upfront Cash : Inapplicable
September 25, 2020
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Solnatide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APEPTICO’s solnatide IMP is the only active ongoing campaign against ARDS in the Europe which assesses an innovative and new therapeutic compound that already delivered proof-of-concept results in two clinical studies in patients with severe lung dysfu...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 05, 2020
Lead Product(s) : Solnatide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apeiron Biologics gets regulatory approvals for Phase II Covid-19 trial
Details : Regulatory approvals obtained for the treatment of 200 COVID-19 patients in Austria, Germany and Denmark; Austrian government to provide significant financial support.
Product Name : APN01
Product Type : Enzyme
Upfront Cash : Inapplicable
February 04, 2020
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable